Jan van Heek
Director/Board Member at MINERVA NEUROSCIENCES, INC.
Net worth: 6 558 $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Fred Ahlholm | M | 58 | 10 years | |
| Geoff Race | M | 63 | 14 years | |
| Rémy Henri Luthringer | M | 63 | 10 years | |
| Aaron Berg | M | 61 | 12 years | |
| Odysseas Kostas | M | 49 | 1 years | |
| Patrice Bonfiglio | F | 40 | 1 years | |
| Diane Sullivan | F | 62 | 1 years | |
| Mark Dipaolo | M | 53 | 1 years | |
| Keith Horn | M | 66 | 1 years | |
| Fouzia Laghrissi-Thodes | M | 61 | 9 years | |
| Paul Cohen | M | 49 | 1 years | |
| Louis Sterling | M | 45 | 1 years | |
| David Kupfer | M | 84 | 9 years | |
| Hans-Peter Hasler | M | 68 | 7 years | |
| Jeryl Hilleman | F | 66 | 6 years | |
| Christine van Heek | F | 67 |
Bio Point Group LLC
| 21 years |
| Howard Goldsweig | M | - |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | 16 years |
| Joseph Reilly | M | 49 | 10 years | |
| David Keenan | M | - | 2 years | |
| Derek Kalinowski | M | - | 13 years | |
| Michael Davidson | M | 74 | 8 years | |
| Nabil A. Abadir | M | - | 2 years | |
| Thomas Reilly | M | 52 | 2 years | |
| Ramana Kuchibhatla | M | - | 3 years | |
| Steven Ketchum | M | 59 | 12 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Thero | M | 63 |
ViaCell, Inc.
 ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 12 years |
| Marc Beer | M | 59 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 13 years |
| Michael J. Farrell | M | 45 | 3 years | |
| Joseph Zakrzewski | M | 60 | 12 years | |
| Rogério Vivaldi Coelho | M | 60 | 7 years | |
| Karim Mikhail | M | 53 | 3 years | |
| Lars Ekman | M | 74 | 14 years | |
| Joseph T. Kennedy | M | 56 | 10 years | |
| Jason Marks | M | 48 | 1 years | |
| Cynthia Fisher | F | 63 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 4 years |
| Murray Stewart | M | 63 | - | |
| Adam Berger | M | - | 1 years | |
| Alfonso Zulueta | M | 61 | 1 years | |
| Stephen D. Schultz | M | - | 2 years | |
| Joseph Anderson | M | 65 | 4 years | |
| Alan S. Roemer | M | 54 |
Azelon Pharmaceuticals, Inc.
 Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | 1 years |
| Francesco de Rubertis | M | 54 | 10 years | |
| Kristine Peterson | F | 64 | 13 years | |
| Michèle Ollier | M | 65 | 10 years | |
| Manus Rogan | M | 55 | 2 years | |
| Elisabeth Schwartz | F | - | - | |
| Nico Vandervelpen | M | 49 | 3 years | |
| William B. Boni | M | - | 6 years | |
| Lisa M. DeFrancesco | F | 45 | - | |
| Devin Smith | M | 56 | - | |
| Mark Levine | M | 51 | 3 years | |
| Bill Doyle | M | 61 | 6 years | |
| Brian R. MacDonald | M | - |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | 7 years |
| Geraldine Murphy | F | - | 1 years | |
| Carl Gordon | M | 59 | 5 years | |
| Erin Enright | F | 63 | 1 years | |
| Patrick O’Sullivan | M | 82 | 11 years | |
| Thomas Gerard Lynch | M | 67 | 10 years | |
| Per Wold-Olsen | M | 76 | 1 years | |
| David M. Stack | M | 72 | 10 years | |
| James Healy | M | 58 | 8 years | |
| Lorenzo Pellegrini | M | - | 7 years | |
| Joseph S. Mohr | M | - |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | - |
| Craig Granowitz | M | 60 | - | |
| Stephen H. Featherstone | M | - |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | 1 years |
| Jay B. Saoud | M | 65 | 4 years | |
| Justine Lalonde | M | - | - | |
| Christoph Adams | M | 67 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 4 years |
| Donna Pasek | F | - | 11 years | |
| Wen Bo Wang | M | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 4 years |
| Anne Cook | F | 62 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 years |
| Ben Harshbarger | M | 55 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 years |
| Jay Mohr | M | - |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | 2 years |
| Jordan Zwick | M | 37 | 1 years | |
| Joseph Balzer | M | - | 2 years | |
| James Haley | M | 51 | 5 years | |
| David Feigal | M | 74 | - | |
| Matthew Bartholomae | M | - | 2 years | |
| Stephan Wnendt | M | 61 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | - |
| William Fodor | M | 65 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 years |
| James Topper | M | 62 |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | - |
| Dan Dunham | M | - | - | |
| Steve G. Dance | M | 72 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 3 years |
| Paul Blake | M | 76 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 years |
| Kirk T. Williamson | M | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | - |
| Justine E. Koenigsberg | F | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | - |
| Mark W. Salyer | M | - | - | |
| Paul Hastings | M | 64 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 7 years |
| Steven Prelack | M | 66 |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | 3 years |
| Kapil Dhingra | M | 64 |
BioVex, Inc.
BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | 2 years |
| Vaughn M. Kailian | M | 79 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 3 years |
| Maxine Gowen | M | 66 |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | - |
| Michael Kalb | M | 53 | 6 years | |
| Christian Bloomgren | M | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 6 years |
| James S. Sigler | M | 63 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 years |
| George Daley | M | - |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | - |
| Richard Russell | M | 60 | 3 years | |
| James Tullis | M | 76 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | 2 years |
| Alan J. Wills | M | 60 | 1 years | |
| Denise Scots-Knight | M | 64 |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 55 | 55.00% |
| Ireland | 47 | 47.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jan van Heek
- Personal Network
